Carisma Therapeutics, Inc.CARMNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -11.55% | -14.83% | +9.77% | -100.00% | +1236.78% |
| Gross Profit Growth | +0.00% | +35.33% | +0.00% | +0.00% | +1236.78% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +3.12% | +2.63% | +2.03% | +0.59% | +0.59% |
| Weighted Average Shares Diluted Growth | +3.12% | +2.63% | +2.03% | +0.59% | +0.95% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | -71.05% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -60.61% | -65.99% | -78.38% | -91.55% | -84.42% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +20.75% | -20.56% | -68.97% | -54.78% | -77.03% |
| R&D Expense Growth | -42.07% | -19.76% | -47.57% | -84.16% | -98.26% |
| SG&A Expenses Growth | -21.40% | +50.34% | -28.25% | -39.68% | -76.19% |